These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 34794654)

  • 21. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial.
    Serruys PW; Farooq V; Kalesan B; de Vries T; Buszman P; Linke A; Ischinger T; Klauss V; Eberli F; Wijns W; Morice MC; Di Mario C; Corti R; Antoni D; Sohn HY; Eerdmans P; Rademaker-Havinga T; van Es GA; Meier B; Jüni P; Windecker S
    JACC Cardiovasc Interv; 2013 Aug; 6(8):777-89. PubMed ID: 23968698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Everolimus-Eluting Versus Biolimus-Eluting Stents With Biodegradable Polymers in Unselected Patients Undergoing Percutaneous Coronary Intervention: A Randomized Noninferiority Trial With 1-Year Follow-Up (SORT OUT VIII Trial).
    Maeng M; Christiansen EH; Raungaard B; Kahlert J; Terkelsen CJ; Kristensen SD; Carstensen S; Aarøe J; Jensen SE; Villadsen AB; Lassen JF; Thim T; Eftekhari A; Veien KT; Hansen KN; Junker A; Bøtker HE; Jensen LO;
    JACC Cardiovasc Interv; 2019 Apr; 12(7):624-633. PubMed ID: 30947936
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ten-Year Clinical Outcomes From a Trial of Three Limus-Eluting Stents With Different Polymer Coatings in Patients With Coronary Artery Disease.
    Kufner S; Joner M; Thannheimer A; Hoppmann P; Ibrahim T; Mayer K; Cassese S; Laugwitz KL; Schunkert H; Kastrati A; Byrne RA;
    Circulation; 2019 Jan; 139(3):325-333. PubMed ID: 30586724
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized Comparison of Ridaforolimus-Eluting and Zotarolimus-Eluting Coronary Stents: 2-Year Clinical Outcomes From the BIONICS and NIREUS Trials.
    Konigstein M; Smits PC; Love MP; Ben-Yehuda O; Ozan MO; Liu M; Perlman GY; Leon MB; Stone GW; Kandzari DE
    JACC Cardiovasc Interv; 2020 Jan; 13(1):86-93. PubMed ID: 31918946
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Polymer-Free Biolimus-Eluting Stents or Polymer-Based Zotarolimus-Eluting Stents for Coronary Bifurcation Lesions.
    Gallone G; D'Ascenzo F; Ielasi A; Landra F; Stefanini GG; Di Biasi M; Mancone M; Tomai F; Infantino V; Rognoni A; Briguori C; Boccuzzi G; Smolka G; Chiarito M; Capodanno D; Chieffo A; Fabbiocchi F; Poli A; Tespili M; D'Urbano M; Giordano A; Escaned J; De Ferrari GM; Sardella G
    Cardiovasc Revasc Med; 2022 Feb; 35():66-73. PubMed ID: 33903036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term (5-year) clinical evaluation of the Resolute zotarolimus-eluting coronary stent: The RESOLUTE US clinical trial.
    Kirtane AJ; Yeung AC; Ball M; Carr J; O'Shaughnessy C; Mauri L; Liu M; Leon MB
    Catheter Cardiovasc Interv; 2020 May; 95(6):1067-1073. PubMed ID: 31301219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. One-year clinical results of the NANO registry: A multicenter, prospective all-comers registry study in patients receiving implantation of a polymer-free sirolimus-eluting stent.
    Liu Y; Zhang Y; Li Y; Qi T; Pan D; Wang H; Liu C; Ma D; Fang Z; Zhang R; Mou F; Tao L;
    Catheter Cardiovasc Interv; 2020 Feb; 95 Suppl 1():658-664. PubMed ID: 31961057
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and Efficacy of Polymer-Free Drug-Eluting Stents.
    Chiarito M; Sardella G; Colombo A; Briguori C; Testa L; Bedogni F; Fabbiocchi F; Paggi A; Palloshi A; Tamburino C; Margonato A; Pivato CA; Baber U; Calcagno S; Giordano A; Godino C; Stefanini GG
    Circ Cardiovasc Interv; 2019 Feb; 12(2):e007311. PubMed ID: 30767663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized Comparison of a Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent With a Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: The SORT OUT VII Trial.
    Jensen LO; Thayssen P; Maeng M; Ravkilde J; Krusell LR; Raungaard B; Junker A; Terkelsen CJ; Veien KT; Villadsen AB; Kaltoft A; Tilsted HH; Hansen KN; Aaroe J; Kristensen SD; Hansen HS; Jensen SE; Madsen M; Bøtker HE; Berencsi K; Lassen JF; Christiansen EH
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polymer-free versus permanent polymer-coated drug eluting stents for the treatment of coronary artery disease: A meta-analysis of randomized trials.
    Nogic J; Baey YW; Nerlekar N; Ha FJ; Cameron JD; Nasis A; West NEJ; Brown AJ
    J Interv Cardiol; 2018 Oct; 31(5):608-616. PubMed ID: 29797804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiographic and clinical comparison of novel Orsiro Hybrid sirolimus-eluting stents and Resolute Integrity zotarolimus-eluting stents in all-comers with coronary artery disease (ORIENT trial): study protocol for a randomized controlled trial.
    Lee JM; Park SD; Lim SY; Doh JH; Cho JM; Kim KS; Bae JW; Chung WY; Youn TJ
    Trials; 2013 Nov; 14():398. PubMed ID: 24257456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical outcomes with reservoir-based polymer-free amphilimus-eluting stents in real-world patients according to diabetes mellitus and complexity: The INVESTIG8 registry.
    Sardella G; Stella P; Chiarito M; Leone AM; Balian V; Prosperi F; Sorropago G; Mancone M; Calcagno S; Briguori C; Stefanini GG
    Catheter Cardiovasc Interv; 2018 Apr; 91(5):884-891. PubMed ID: 28707375
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 1-Year Clinical Outcomes of All Comers Treated With 2 Bioresorbable Polymer-Coated Sirolimus-Eluting Stents: Propensity Score-Matched Comparison of the COMBO and Ultrathin-Strut Orsiro Stents.
    Chandrasekhar J; Kok MM; Kalkman DN; Aquino MB; Zocca P; Woudstra P; Beijk MA; Kerkmeijer LS; Sartori S; Baber U; Tijssen JG; Koch KT; Dangas GD; Colombo A; Pocock S; von Birgelen C; Mehran R; de Winter RJ;
    JACC Cardiovasc Interv; 2020 Apr; 13(7):820-830. PubMed ID: 32273094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 5-Year Safety and Efficacy of Resolute Zotarolimus-Eluting Stent: The RESOLUTE Global Clinical Trial Program.
    Yeh RW; Silber S; Chen L; Chen S; Hiremath S; Neumann FJ; Qiao S; Saito S; Xu B; Yang Y; Mauri L
    JACC Cardiovasc Interv; 2017 Feb; 10(3):247-254. PubMed ID: 28109872
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized Trial of Polymer-Free Sirolimus- and Probucol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial.
    Kufner S; Sorges J; Mehilli J; Cassese S; Repp J; Wiebe J; Lohaus R; Lahmann A; Rheude T; Ibrahim T; Massberg S; Laugwitz KL; Kastrati A; Byrne RA;
    JACC Cardiovasc Interv; 2016 Apr; 9(8):784-792. PubMed ID: 27017366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomized Comparison of the Polymer-Free Biolimus-Coated BioFreedom Stent With the Ultrathin Strut Biodegradable Polymer Sirolimus-Eluting Orsiro Stent in an All-Comers Population Treated With Percutaneous Coronary Intervention: The SORT OUT IX Trial.
    Jensen Lisette Okkels; Maeng M; Raungaard B; Kahlert J; Ellert J; Jakobsen L; Villadsen AB; Veien KT; Kristensen SD; Ahlehoff O; Carstensen S; Christensen MK; Terkelsen CJ; Engstroem T; Hansen KN; Bøtker HE; Aaroe J; Thim T; Thuesen L; Freeman P; Aziz A; Eftekhari A; Junker A; Jensen SE; Lassen JF; Hansen HS; Christiansen EH;
    Circulation; 2020 Jun; 141(25):2052-2063. PubMed ID: 32434381
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical outcomes of real-world patients treated with an amphilimus polymer-free stent versus new generation everolimus-eluting stents.
    Panoulas VF; Latib A; Naim C; Sato K; Ielasi A; Tespili M; Godino C; Testa L; Bedogni F; Colombo A
    Catheter Cardiovasc Interv; 2015 Dec; 86(7):1168-76. PubMed ID: 26269415
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Five-year clinical outcome of multicenter randomized trial comparing amphilimus - with paclitaxel-eluting stents in de novo native coronary artery lesions.
    Carrié D; Berland J; Verheye S; Hauptmann KE; Vrolix M; Musto C; Berti S; Dibié A; Maupas E; Antoniucci D; Schofer J
    Int J Cardiol; 2020 Feb; 301():50-55. PubMed ID: 31759686
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen), a randomized, controlled, noninferiority trial.
    Park KW; Kang SH; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Hur SH; Ryu JK; Lee BR; Park YW; Chae IH; Kim HS;
    J Am Coll Cardiol; 2014 Jul; 63(25 Pt A):2805-16. PubMed ID: 24814486
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.